tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

INMB Stock Latest News

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer’s Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
Press ReleasesINmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer’s Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
3d ago
INMB
INmune Bio announces results of additional interim analysis of Phase 2 trial
PremiumThe Fly
INmune Bio announces results of additional interim analysis of Phase 2 trial
3d ago
INMB
INmune Bio Announces $13.0 Million Registered Direct Offering
PremiumPress Releases
INmune Bio Announces $13.0 Million Registered Direct Offering
7d ago
INMB
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
PremiumPress Releases
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
17d ago
INMB
INmune Bio initiated with an Outperform at Scotiabank on Alzheimer’s potential
PremiumThe Fly
INmune Bio initiated with an Outperform at Scotiabank on Alzheimer’s potential
29d ago
INMB
Scotiabank starts INmune with Outperform on Alzheimer’s potential
PremiumThe FlyScotiabank starts INmune with Outperform on Alzheimer’s potential
29d ago
INMB
INmune Bio initiated with an Outperform at Scotiabank
Premium
The Fly
INmune Bio initiated with an Outperform at Scotiabank
30d ago
INMB
INmune Bio reports Q2 EPS (50c), consensus (63c)
Premium
The Fly
INmune Bio reports Q2 EPS (50c), consensus (63c)
2M ago
INMB
INmune Bio announces new Phase 1 study data on XPro
PremiumThe Fly
INmune Bio announces new Phase 1 study data on XPro
2M ago
INMB
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
PremiumPress Releases
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
2M ago
INMB
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
PremiumPress Releases
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
2M ago
INMB
INmune Bio announces publication on INKmune
PremiumThe Fly
INmune Bio announces publication on INKmune
2M ago
INMB
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
PremiumPress ReleasesINmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
2M ago
INMB
INmune Bio completes blinded interim analysis of Phase II Alzheimer’s trial
Premium
The Fly
INmune Bio completes blinded interim analysis of Phase II Alzheimer’s trial
3M ago
INMB
INmune Bio director buys 5K shares of common stock
Premium
The Fly
INmune Bio director buys 5K shares of common stock
3M ago
INMB
Inmune Bio Grants CEO Stock Options Under Incentive Plan
PremiumCompany Announcements
Inmune Bio Grants CEO Stock Options Under Incentive Plan
3M ago
8K
INMB
INmune Bio to join Russell 3000 Index
PremiumThe Fly
INmune Bio to join Russell 3000 Index
4M ago
INMB
INmune Bio Inc. to Join Russell 3000® Index
PremiumPress Releases
INmune Bio Inc. to Join Russell 3000® Index
4M ago
INMB
Inmune Bio Inc Grants Stock Options to Top Executives
PremiumCompany Announcements
Inmune Bio Inc Grants Stock Options to Top Executives
4M ago
8K
INMB
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
PremiumPress ReleasesINmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
4M ago
INMB
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
Premium
Press Releases
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
5M ago
INMB
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
5M ago
ALT
APLS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >